Johanniter GmbH — Clinical Trial Site

24 Registered trials

9 Currently recruiting

Organisation

Johanniter GmbH

Location

Bonn, Germany

Identifier

ORG-100047333

Address

Wendstrasse 31, 39576, Germany

Departments

Abteilung fuer Innere Medizin, Hämatologie und Onkologie
Hämatologie und Onkologie
Hämatologie, Internistische Onkologie
Innere Abteilung
Innere Medizin
Innere Medizin I
Internal medicine
Internal Medicine Hematooncology
Johanniter Krankenhaus Bonn
Johanniter-Krankenhaus Stendal Gynäkologisches Krebszentrum
Johanniter-Krankenhaus und Waldkrankenhaus Bonn
Klinik für Frauenheilkunde und Geburtshilfe
N/A
Onkologie und Hämatologie
Onkologisches Zentrum
Urology

Clinical trials at this site (24)

Search interface

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Pending

2025-524408-30-01 Metastatic hormone-sensitive prostate cancer 5
PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting

2023-504445-31-00 Carcinoma, Head and Neck 4 2024-09-19
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Diffuse Large B-Cell Lymphoma (DLBCL) 4 2025-05-16
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 4 2021-05-31
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended

2022-500674-34-00 Marginal Zone Lymphoma 4 2019-11-04
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984)… Ended

2024-511791-32-00 Multiple Myeloma 4 2017-08-15
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet… Ended

2022-502338-20-00 Polycythemia vera 6 2023-07-28
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15